Millenia Hope Inc. Providing Hope to Humanity

Millenia Hope Appoints President - Biotech industry veteran to run day to day operations

Montreal (PRWEB) April 17, 2005 -- Millenia Hope Inc., a Biotech Corporation (OTCBB-MLHP) (Berlin-MLF), announced today that Margaret (Maggie) Bywater has joined the company as President. Bywater started her scientific career in the field of genetics of disease in the 1970s. She received her degree from the Medical Faculty at the University of Uppsala Sweden (1975), where she did a masters in Molecular Pathology. She was associated with the university for more than a decade.

Her business career started in biotech/healthcare at Pharmacia in Sweden, where she helped develop and market a diagnostic system to identify genetic markers in breast cancer predicting response to therapy. During the past two decades she held positions, including clinical operations and technology transfer, in both start-ups and large corporations in Europe and US. She was corporate Staff Vice President-Pharmaceutical Business Development at The Perkin Elmer Corporation in the US, a $1.3 billion biotech, where she was involved in corporate strategy for mergers and acquisitions. As General Manager of the newly acquired PE GenScope, in California, she became familiar with executive sales of high ticket transactions with pharma. In Canada she was president of two early stage drug discovery companies.

Maggie comes to Millenia Hope from H3 Pharma, Montreal, as Vice President of Business Development & Licensing. She headed new medications acquisitions, managed due diligence, and negotiated and structured deals, in-licensing for clinical development and out-licensing for distribution, marketing and sales. Maggie has an extensive clinical network, in academia and healthcare.

Leonard Stella, CEO Millenia Hope, stated, Maggie has a strong background in biotech business transactions, operations and intellectual property. I am delighted to welcome Maggie in the Presidents role at Millenia, at this time in our companys development." He continued, Millenia Hope has the right to sell MMH Malarex/MMH-18 in 16 countries and is involved in ongoing discussions with distribution candidates in malaria markets. Maggie will lead the commercialization of our product and manage the R&D team in the clinical studies underway in four African countries."

About Millenia Hope:

Millenia Hope develops innovative treatments and quality products that will increase the quality of life, provide tools in the fight against devastating diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.

Safe Harbor Statement:

Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.

For more information:

Please contact: Mr. Hugo Valente

Tel: 514 846-5757 0r 514 288-8822

Fax: 514 935-9758

www.milleniahope.com

hugo@milleniahope.com

# # #